IP Library Granted Patent US 7,972,799
Granted Patent B2
US 7,972,799 · App. 12/388,029 · Granted Jul 5, 2011

Method for determining sepsis using pro-ADM

Assignee: B.R.A.H.M.S. GmbH
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,972,799
App. No.
12/388,029
Granted
Jul 5, 2011
Kind
B2
Abstract

Uses of recombinant procalcitonin 3-116 in the diagnosis and therapy of septic diseases and the measurement of prohormones other than procalcitonin, and of dipeptidyl peptidase IV, as biomarkers in the diagnosis of sepsis.

Claims (16)

1. A method for the detection of sepsis in an individual suspected of having sepsis, comprising;

contacting a blood, plasma or serum sample from the individual with an antibody which binds to human pro-adrenomedullin (pro-ADM) and/or a partial peptide thereof, and

determining the level of human pro-ADM and/or said partial peptide, wherein an increase in said level compared to healthy individuals is indicative of sepsis

wherein said partial peptide differs from the known complete peptide sequence of human pro-ADM by the absence of the first two amino acids at the amino terminus thereof or consists of amino acids 45-92 of pro-ADM.

2. The method of claim 1 for differential-diagnostic early detection of sepsis.

3. The method of claim 1 for assessment of the severity of sepsis or a sepsis-like systemic infection.

4. The method of claim 1 for assessment of the success of a therapeutic treatment of sepsis or a severe sepsis-like infection.

5. The method of claim 1 further comprising determination of at least one other indicator of sepsis.

6. The method of claim 5 wherein said at least one other indicator of sepsis is procalcitonin.

7. The method according to claim 1 , wherein a partial peptide of human pro-ADM is detected which differs from the known complete peptide sequence of human pro-ADM by the absence of the first two amino acids at the amino terminus thereof.

8. The method of claim 7 wherein said dipeptide is cleavable by dipeptidyl-aminopeptidase IV (DP IV; DAP IV or CD26).

9. The method according to claim 1 , wherein said determination of human pro-ADM and/or said partial peptide is carried out as an immunoassay or a precipitation assay, and a diagnosis of the presence of sepsis or severe sepsis-like infections is made if the concentration of pro-ADM and/or said partial peptide determined is significantly higher than the concentration observed in healthy persons.

10. A method for the detection of sepsis in an individual suspected of having sepsis, comprising;

contacting a blood, plasma or serum sample from the individual with an antibody which binds to human pro-adrenomedullin (pro-ADM) and/or a partial peptide thereof, and

determining the level of binding of said antibody, wherein an increase in said level compared to healthy individuals is indicative of sepsis

wherein said partial peptide differs from the known complete peptide sequence of human pro-ADM by the absence of the first two amino acids at the amino terminus thereof or consists of amino acids 45-92 of pro-ADM.

Assignments (2)
CHANGE OF NAME Recorded Feb 9, 2011
From: BRAHMS AKTIENGESELLSCHAFT (AG)
To: B.R.A.H.M.S. GMBH
Reel/Frame 030574/0321 →
CHANGE OF NAME Recorded Nov 29, 2010
From: BRAHMS AKTIENGESELLSCHAFT
To: B.R.A.H.M.S GMBH
Reel/Frame 025428/0530 →
Priority Claims (1)
DE 198 47 690 · Oct 15, 1998 · national
Continuity (3)
Division 10808368 · Mar 25, 2004
Division 09806437
Related Publication 20090215076A1 · Aug 27, 2009